1 |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018 [J]. CA Cancer J Clin, 2018, 68(1): 7-30. doi:10.3322/caac.21442
doi: 10.3322/caac.21442
|
2 |
DO H T T, LEE C H, CHO J. Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers [J]. Cancers (Basel), 2020, 12(2): 287-311. doi:10.3390/cancers12020287
doi: 10.3390/cancers12020287
|
3 |
LI H, WU M, ZHAO X. Role of chemokine systems in cancer and inflammatory diseases [J]. Med Comm (2020), 2022, 3(2): e147-87. doi:10.1002/mco2.147
doi: 10.1002/mco2.147
|
4 |
WU Y, SHEN Y, CHANG J, et al. Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro [J]. Cytokine, 2018, 110(10): 94-103. doi:10.1016/j.cyto.2018.04.027
doi: 10.1016/j.cyto.2018.04.027
|
5 |
NAZEMI M, RAINERO E. Cross-Talk Between the Tumor Microenvironment, Extracellular Matrix, and Cell Metabolism in Cancer [J]. Front Oncol, 2020, 10(2): 239-245. doi:10.3389/fonc.2020.00239
doi: 10.3389/fonc.2020.00239
|
6 |
ZENG Z, LAN T, WEI Y, et al. CCL5/CCR5 axis in human diseases and related treatments [J]. Genes Dis, 2022, 9(1): 12-27. doi:10.1016/j.gendis.2021.08.004
doi: 10.1016/j.gendis.2021.08.004
|
7 |
BLATTNER C, FLEMING V, WEBER R, et al. CCR5(+) Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions [J]. Cancer Res, 2018, 78(1): 157-167. doi:10.1158/0008-5472.can-17-0348
doi: 10.1158/0008-5472.can-17-0348
|
8 |
NIE Y, HUANG H, GUO M, et al. Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy [J]. Clin Cancer Res, 2019, 25(13): 3873-3886. doi:10.1158/1078-0432.ccr-18-3421
doi: 10.1158/1078-0432.ccr-18-3421
|
9 |
GONZALEZ-MARTIN A, GOMEZ L, LUSTGARTEN J, et al. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells [J]. Cancer Res, 2011, 71(16): 5455-5466. doi:10.1158/0008-5472.can-11-1687
doi: 10.1158/0008-5472.can-11-1687
|
10 |
LIU J, MA X, CAI L, et al. Downregulation of both gene expression and activity of Hsp27 improved maturation of mouse oocyte in vitro [J]. Reprod Biol Endocrinol, 2010, 8(5): 47-58. doi:10.1186/1477-7827-8-47
doi: 10.1186/1477-7827-8-47
|
11 |
HE W, YANG T, GONG X, et al. Targeting CXC motif chemokine receptor 4 inhibits the proliferation, migration and angiogenesis of lung cancer cells [J]. Oncol Lett, 2018, 16(3): 3976-3982. doi:10.3892/ol.2018.9076
doi: 10.3892/ol.2018.9076
|
12 |
LIU H, YANG Z, LU W, et al. Chemokines and chemokine receptors: A new strategy for breast cancer therapy [J]. Cancer Med, 2020, 9(11): 3786-3799. doi:10.1002/cam4.3014
doi: 10.1002/cam4.3014
|
13 |
CASAGRANDE N, BORGHESE C, VISSER L, et al. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth [J]. Haematologica, 2019, 104(3): 564-575. doi:10.3324/haematol.2018.196725
doi: 10.3324/haematol.2018.196725
|
14 |
XU J, LI J, CHEN Q, et al. Advances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer [J]. Front Pharmacol, 2022, 13(6): 920779. doi:10.3389/fphar.2022.920779
doi: 10.3389/fphar.2022.920779
|
15 |
VELASCO-VELAZQUEZ M, XOLALPA W, PESTELL R G. The potential to target CCL5/CCR5 in breast cancer [J]. Expert Opin Ther Targets, 2014, 18(11): 1265-1275. doi:10.1517/14728222.2014.949238
doi: 10.1517/14728222.2014.949238
|
16 |
HAWILA E, RAZON H, WILDBAUM G, et al. CCR5 Directs the Mobilization of CD11b(+)Gr1(+)Ly6C(low) Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development [J]. Cell Rep, 2017, 21(8): 2212-2222. doi:10.1016/j.celrep.2017.10.104
doi: 10.1016/j.celrep.2017.10.104
|
17 |
NISHIKAWA G, KAWADA K, NAKAGAWA J, et al. Bone marrow- derived mesenchymal stem cells promote colorectal cancer progression via CCR5 [J]. Cell Death Dis, 2019, 10(4): 264-276. doi:10.1038/s41419-019-1508-2
doi: 10.1038/s41419-019-1508-2
|
18 |
SINGH S K, MISHRA M K, ELTOUM I A, et al. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells [J]. Sci Rep, 2018, 8(1): 1323-1334. doi:10.1038/s41598-018-19643-0
doi: 10.1038/s41598-018-19643-0
|
19 |
YANG L, WANG B, QIN J, et al. Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer [J]. Immunopharmacol Immunotoxicol, 2018, 40(1): 91-97. doi:10.1080/08923973.2017.1417997
doi: 10.1080/08923973.2017.1417997
|
20 |
TANABE Y, SASAKI S, MUKAIDA N, et al. Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation [J]. Oncotarget, 2016, 7(30): 48335-48345. doi:10.18632/oncotarget.10227
doi: 10.18632/oncotarget.10227
|
21 |
叶美凤,苏珊,岑文昌,等. 粟粒型肺癌的肿瘤微环境及其与EGFR-TKI疗效的关系[J]. 实用医学杂志,2021,37(2):250-254. doi:10.3969/j.issn.1006-5725.2021.02.023
doi: 10.3969/j.issn.1006-5725.2021.02.023
|
22 |
MORAN C J, ARENBERG D A, HUANG C, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma [J]. Clin Cancer Res, 2002, 8(12): 3803-3812.
|
23 |
TANG J, RAMIS-CABRER D, CURULL V, et al. Immune Cell Subtypes and Cytokines in Lung Tumor Microenvironment: Influence of COPD [J]. Cancers (Basel), 2020, 12(5): 1217-1231. doi:10.3390/cancers12051217
doi: 10.3390/cancers12051217
|
24 |
SEDIGHZADEH S S, KHOSHBIN A P, RAZI S, et al. A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications [J]. Transl Lung Cancer Res, 2021, 10(4): 1889-1916. doi:10.21037/tlcr-20-1241
doi: 10.21037/tlcr-20-1241
|
25 |
SELIGER B, MASSA C. Immune Therapy Resistance and Immune Escape of Tumors [J]. Cancers (Basel), 2021, 13(3): 551-565. doi:10.3390/cancers13030551
doi: 10.3390/cancers13030551
|
26 |
HASLAM A, PRASAD V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs [J]. JAMA Netw Open 2019, 2(5): e192535. doi:10.1001/jamanetworkopen.2019.2535
doi: 10.1001/jamanetworkopen.2019.2535
|
27 |
WANG J, SAUNG M T, LI K, et al. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma [J]. J Exp Med, 2022, 219(5): e20211631. doi:10.1084/jem.20211631
doi: 10.1084/jem.20211631
|
28 |
HAAG G M, SPRINGFELD C, GRUN B, et al. Pembrolizumab and maraviroc in refractory mismatch repair proficient/ microsatellite-stable metastatic colorectal cancer-The PICCASSO phase I trial [J]. Eur J Cancer, 2022, 167(5): 112-122. doi:10.1016/j.ejca.2022.03.017
doi: 10.1016/j.ejca.2022.03.017
|